Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
621-640 of 1,738 trials

Advanced Lung Cancer: Adagrasib and Pembrolizumab Study

We are testing a new treatment combining adagrasib with pembrolizumab for patients with advanced non-small cell lung cancer with a KRAS G12C mutation. The goal is to see if this combination works better than pembrolizumab alone.

Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Medical Cannabis Aerosol for Diabetic Peripheral Neuropathic Pain

We are studying whether a medical cannabis aerosol can help reduce pain for people with diabetic peripheral neuropathic pain. Participants will compare different doses of THC to a placebo to assess pain relief and quality of life.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)Investigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNeurology

Eosinophilic Esophagitis: BP1.7881 Treatment Study

We are testing a new medication, BP1.7881, for adults with eosinophilic esophagitis to see if it can improve their condition. The study will also look at how safe and well-tolerated the treatment is.

Eosinophilic Esophagitis3-6 monthsEfficacy phase (II)≤5 visitsPartially RemoteAllergologyGastroenterology

High-Grade Glioma in Children: Larotrectinib Treatment

We are studying the effects of larotrectinib on young children with newly diagnosed high-grade glioma that has an NTRK fusion. The trial will help us understand how well it works and its safety when used alone or with chemotherapy.

High Grade Glioma (HGG)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Acute Vaginal Infection: BGY-1601-VT Tablet

We are studying a new vaginal tablet for women with acute vaginal infections to see if it works better than a placebo. The trial will help us understand its safety and effectiveness for conditions like Bacterial Vaginosis and Vulvovaginal Candidiasis.

Gynecological Conditions1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesGynecology and ObstetricsInfectious Diseases

Hypertrophic Cardiomyopathy: Aficamten Study

We are evaluating the long-term safety and tolerability of aficamten in adults with hypertrophic cardiomyopathy. The study also looks at its effects on heart function in patients with obstructive HCM.

Hypertrophic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Autoimmune Disease: Ianalumab Delivery Methods

We are comparing two ways to deliver ianalumab to adults with autoimmune diseases. This study will help us understand how well the medication works and its safety when given in different forms.

Sjögren's DiseaseRheumatoid ArthritisSystemic Lupus Erythematosus6-12 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

Graft-Versus-Host Disease Prevention: CY-MET-RIC Study

We are testing two different treatment plans to see which better prevents severe graft-versus-host disease in patients receiving matched-donor transplants. This study will also evaluate overall survival and other important health outcomes.

Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases

Ivosidenib for Acute Myeloid Leukemia After Stem Cell Transplant

We are studying whether Ivosidenib can help patients with acute myeloid leukemia or high-risk myelodysplastic neoplasia stay healthy after a stem cell transplant. This trial focuses on those with an IDH1 mutation to see if it improves their chances of remaining disease-free.

Acute Myeloid Leukemia (AML)Myelodysplastic Neoplasia (MDS)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Small Cell Lung Cancer: AL8326 Treatment Study

We are evaluating the safety and effectiveness of the drug AL8326 for patients with small cell lung cancer who have already received prior treatment. This study aims to find the best dose and understand how well the drug works.

Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPulmonology

Idiopathic Pulmonary Fibrosis: Buloxibutid Study

We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.

Idiopathic Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Lung Cancer: Repotrectinib for Elderly Patients

We are studying the effectiveness of Repotrectinib in frail or elderly patients with advanced lung cancer. The trial aims to see if this treatment can improve tumor response and overall health.

Stage III/IV Non-Small-Cell Lung Cancer with ROS1 Rearrangement>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyPulmonology

Metastatic Uveal Melanoma: Tebentafusp Treatment

We are studying the effects of tebentafusp in patients with metastatic uveal melanoma that has spread to the liver. The goal is to see if it can help achieve complete responses and improve disease control.

Uveal Melanoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesOncology

Sotagliflozin for Post-Bariatric Hypoglycaemia

We are studying whether sotagliflozin can help people who have low blood sugar after weight loss surgery. Participants will receive either the medication or a placebo to compare effects on blood sugar levels.

Postbariatric Hypoglycemia≤3 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementEndocrinologyInternal Medicine

Primary Immune Thrombocytopenia: Belantamab Mafodotin Study

We are investigating a new treatment for adults with primary immune thrombocytopenia who have previously received other therapies. The study aims to assess the safety and effectiveness of this new drug.

Primary Immune Thrombocytopenia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematology

Advanced Solid Tumors: TransCon IL-2 β/γ Treatment Study

We are investigating the safety and tolerability of TransCon IL-2 β/γ alone and with other cancer therapies for adults with advanced solid tumors. This study aims to find the best dose and understand how it works in combination with existing treatments.

Advanced Solid Tumor Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Targeted Anti-Cancer Drugs: DRUP Trial

We are studying how well existing targeted drugs work for patients with advanced cancers that have specific genetic markers. This trial aims to improve access to effective treatments and gather important data on their use.

Non-Hodgkin LymphomaAdvanced Solid TumorT-cell Prolymphocytic Leukemia3-6 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Extrahepatic Cholangiocarcinoma: Durvalumab with Radiofrequency Ablation

We are studying a new treatment combining durvalumab and radiofrequency ablation for patients with bile duct cancer. The goal is to see if this combination improves effectiveness and safety compared to standard therapies.

Extrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Heart Attack Treatment: RTP-026 Study

We are exploring a new medication, RTP-026, for patients who have had a heart attack. The study will assess its safety and effectiveness compared to a placebo.

Heart Attack (Acute Myocardial Infarction)1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Kidney Function: Vonafexor Study

We are studying the effects of vonafexor on kidney function in people with impaired renal function and suspected MASH. The trial will help us understand how different doses impact kidney health and safety.

Impaired Renal Function and Suspected MASH6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyNephrology